MAPT and Alzheimer disease: Notably, Phase 2 clinical trial is underway for the drug called Ambroxol (a mucolytic active product of the prodrug Bromhexine) against the CSF levels of tau and α-synuclein after observing encouraging CSF availability of the drug and notable improvement in the unified Parkinson’s disease rating scale among participants (unpublished, presented at the 2018 AD/PD conference).